Follow Us      

LOGIN
 
Share Page:
Back

Volume 37 , Issue 2
March/April 2017

Pages 219225


The Use of Recombinant Human Platelet-Derived Growth Factor for Maxillary Sinus Augmentation

Atsushi Kubota, DDS, PhD/Hector Sarmiento, DMD, MSc/Mohammed Saad Alqahtani/Arturo Llobell, DDS, MSc/Joseph P. Fiorellini, DMD, DMSc


PMID: 28196162
DOI: 10.11607/prd.2776

The maxillary sinus augmentation procedure has become a predictable treatment to regenerate bone for implant placement. The purpose of this study was to evaluate the effect of recombinant human platelet-derived growth factor BB (rhPDGF-BB) combined with a deproteinized cancellous bovine bone graft for sinus augmentation. The lateral window approach was used for maxillary sinuses with minimal residual bone. After a healing period of 4 months, dental implants were placed and then restored following a 2-month osseointegration period. The result demonstrated increased bone height and ISQ values and a 100% survival rate. This study indicates that the addition of rhPDGF-BB to deproteinized cancellous bovine bone accelerated the healing period in maxillary sinuses with minimal native bone.


Full Text PDF File | Order Article

 

 
Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.

 

© 2018 Quintessence Publishing Co, Inc

PRD Home
Current Issue
Ahead of Print
Archive
Author Guidelines
About
Submission Form
Submit
Reprints
Permission
Advertising
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us
Help